These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 33129609)

  • 61. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
    Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
    Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
    Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vaccines: countering anthrax: vaccines and immunoglobulins.
    Grabenstein JD
    Clin Infect Dis; 2008 Jan; 46(1):129-36. PubMed ID: 18171228
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.
    Klinman DM; Yamamoto M; Tross D; Tomaru K
    Expert Opin Biol Ther; 2009 Dec; 9(12):1477-86. PubMed ID: 19769541
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R; Gupta PK; Banerjea AC; Singh Y
    Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 69. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Klinman DM; Xie H; Little SF; Currie D; Ivins BE
    Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Compatible co-administration of BioThrax® vaccine and ciprofloxacin-Results of a randomized open-label drug-vaccine interaction trial.
    Cassie D; Longstreth J; Hopkins R; Hunter-Stitt E; Drobic B; Bellani M
    Vaccine X; 2024 Mar; 17():100431. PubMed ID: 38352727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mobility network models of COVID-19 explain inequities and inform reopening.
    Chang S; Pierson E; Koh PW; Gerardin J; Redbird B; Grusky D; Leskovec J
    Nature; 2021 Jan; 589(7840):82-87. PubMed ID: 33171481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome: Clinical Development of a Calcium Release-Activated Calcium Channel Inhibitor.
    Bruen C; Miller J; Wilburn J; Mackey C; Bollen TL; Stauderman K; Hebbar S
    Pancreas; 2021 Apr; 50(4):537-543. PubMed ID: 33939666
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
    Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
    Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.
    Henning L; Anderson M; Triplett C; Smith T; Boyce K; Hendey L; Ridenour A; Eng J; Schaeufele D; Wilson E; Sabourin CL; Adams LE; Babas T; Parish L; Wolfe D
    Hum Vaccin Immunother; 2023 Dec; 19(3):2290345. PubMed ID: 38115181
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.
    Bower WA; Yu Y; Person MK; Parker CM; Kennedy JL; Sue D; Hesse EM; Cook R; Bradley J; Bulitta JB; Karchmer AW; Ward RM; Cato SG; Stephens KC; Hendricks KA
    MMWR Recomm Rep; 2023 Nov; 72(6):1-47. PubMed ID: 37963097
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anthrax revisited: how assessing the unpredictable can improve biosecurity.
    Sabra DM; Krin A; Romeral AB; Frieß JL; Jeremias G
    Front Bioeng Biotechnol; 2023; 11():1215773. PubMed ID: 37795173
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.